Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

136 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.
De Placido S, Gallo C, De Laurentiis M, Bisagni G, Arpino G, Sarobba MG, Riccardi F, Russo A, Del Mastro L, Cogoni AA, Cognetti F, Gori S, Foglietta J, Frassoldati A, Amoroso D, Laudadio L, Moscetti L, Montemurro F, Verusio C, Bernardo A, Lorusso V, Gravina A, Moretti G, Lauria R, Lai A, Mocerino C, Rizzo S, Nuzzo F, Carlini P, Perrone F; GIM Investigators. De Placido S, et al. Among authors: carlini p. Lancet Oncol. 2018 Apr;19(4):474-485. doi: 10.1016/S1470-2045(18)30116-5. Epub 2018 Feb 23. Lancet Oncol. 2018. PMID: 29482983 Clinical Trial.
Exemestane or tamoxifen?
Ferretti G, Felici A, Carlini P, Cognetti F. Ferretti G, et al. Among authors: carlini p. Lancet. 2007 May 12;369(9573):1599; author reply 1600-1. doi: 10.1016/S0140-6736(07)60739-9. Lancet. 2007. PMID: 17499594 No abstract available.
Early recurrence risk: aromatase inhibitors versus tamoxifen.
Bria E, Carlini P, Cuppone F, Vaccaro V, Milella M, Cognetti F. Bria E, et al. Among authors: carlini p. Expert Rev Anticancer Ther. 2010 Aug;10(8):1239-53. doi: 10.1586/era.10.54. Expert Rev Anticancer Ther. 2010. PMID: 20735310 Review.
136 results